Humanized monoclonal antibodies Mylotarg

Gemtuzumab ozogamicin (Mylotarg) consists of a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic enediyne antibiotic calicheamicin. It has been used to treat a subset of patients with acute myeloid leukemia in association with topotecan -I- cytarabine. Its most common adverse effects are myelosuppression, increased hepatic enzyme activity, infections, fever and chills, bleeding, nausea and vomiting, and dyspnea. 

---